InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept StudiesNewsfile Corp • 10/24/23
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business UpdateNewsfile Corp • 09/29/23
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price ComplianceNewsfile Corp • 09/22/23
InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ETNewsfile Corp • 07/21/23
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis BullosaNewsfile Corp • 06/22/23
InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience MeetingNewsfile Corp • 06/01/23
InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ETNewsfile Corp • 05/18/23
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business UpdateNewsfile Corp • 05/15/23
InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis BullosaNewsfile Corp • 03/28/23
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 02/17/23
InMed Announces Appointment of Interim Chief Financial Officer and Change of AuditorGlobeNewsWire • 12/12/22
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to MarketGlobeNewsWire • 11/21/22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to MarketGlobeNewsWire • 11/18/22
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases ProgramZacks Investment Research • 11/17/22
InMed stock rockets after research grant awarded for cannabinoid analogs to treat Alzheimer's, Parkinson'sMarket Watch • 11/16/22
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/11/22